Adult drug effective for pediatric patients with dilated cardiomyopathy and heart failure

by from the Food and Drug Administration's Center for Drug Evaluation and Research, Division of Cardiovascular and Renal Products, Division of Pediatric and Maternal Health, and Office of Pediatric Therapeutics

The Food and Drug Administration (FDA) has approved ivabradine (Corlanor) for treatment of heart failure (HF) in children with dilated cardiomyopathy (DCM).

Pediatric DCM typically has a poor prognosis with significant morbidity. About 40% of children progress to cardiac transplant or death within five years after diagnosis (Pahl E, et al. J Am Coll Cardiol. 2012;59:607-615).

Because approved drug therapies for pediatric HF have not been available, children with HF due to DCM are treated primarily off-label with drugs approved for adult HF.

In a study of adults with HF from multiple etiologies including DCM, ivabradine reduced HF hospitalization (Swedberg K, et al. Lancet. 2010;376:875-885). Heart rate (HR) reduction was the plausible mechanism for ivabradine's benefit in this study. Thus, if a randomized, controlled trial demonstrated HR reduction in treated pediatric patients, benefit could be inferred and efficacy could be extrapolated from adults to pediatric patients.

The primary efficacy endpoint, 20% reduction in HR without inducing bradycardia, was assessed in a study of 116 children ages 6 months and older with HF due to DCM and elevated baseline HR. This HR reduction was attained in 70% of the ivabradine group compared to 12% on placebo (p<0.0001). No novel safety issues were discovered. A new oral solution was developed for use in pediatric patients.

Resources

- More information about FDA approval of ivabradine, including the trial in adult HF patients
- Additional FDA Update columns